Overall Score

Financial Risk

Balance sheet liquidity remains strong with a current ratio of 4.94 and cash ratio of 0.49.

Leverage is manageable with debt-to-equity of 1.57 and debt-to-assets of 0.34, but the company still carries meaningful financial leverage at 4.69x.

Negative profitability and cash flow metrics remain a key risk, including net margin of -2.00, operating margin of -2.04, and free cash flow per share of -1.77.

Operational Risk

Gross margin is still healthy at 77.1%, but operating efficiency remains weak given negative EBIT margin of -1.98 and operating cash flow margin of -1.77.

Working capital efficiency is mixed, with a long cash conversion cycle of 174.9 days and inventory days of 142.0.

High SG&A intensity at 2.64x revenue continues to pressure operating performance.

Valuation Risk

Valuation remains elevated on sales at 6.05x price-to-sales and 6.78x EV-to-sales.

Price-to-book is also rich at 9.77x, which leaves limited margin of safety if execution weakens.

Negative earnings and cash flow multiples underscore that the stock is still priced on future expectations rather than current fundamentals.

Catalyst Risk

No recent news was provided, so there is no new catalyst to offset the existing operating and profitability risks.

The company’s strong liquidity provides some flexibility, but sustained losses mean future upside likely depends on clinical or commercial execution.

Without fresh updates, the risk profile remains driven by the same underlying fundamentals.